secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-05-29T20:05:20+00:00
Accession:  0001193125-26-248244
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Therapeutics annual meeting elects directors, ratifies auditor, approves executive compensation
--------------------------------------------------------------------------------

- Directors Paul L. Berns, Matthew Fust, David Piacquad elected with ~126M, ~125M, ~127M votes for, respectively; ~25M broker non-votes.
- Ernst & Young ratified as independent auditor for FY 2026 with 157.6M votes for, 53.6K against.
- Advisory vote on named executive officer compensation approved: 132.0M for, 420.9K against, 25.0M broker non-votes.
- Advisory vote on say-on-pay frequency: majority selected one year; company will hold annual advisory votes on executive compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526248244/0001193125-26-248244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526248244/d18793d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-248244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer